CoChat
Sign Up
Cited by 73Growth Hormone and Insulin-like Growth FactorsDoping in SportsGenetics and Physical Performance

Short-term administration of supraphysiological recombinant human growth hormone (GH) does not increase maximum endurance exercise capacity in healthy, active young men and women with normal GH-insulin-like growth factor I axes

Berggren, Annika, Ehrnborg, Christer, Rosén, Thord, Ellegård, Lars, Bengtsson, Bengt-Åke, Caidahl, Kenneth·2005·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jc.2004-1209
Open this paper in CoChat — free account

Abstract

CONTEXT: Despite the fact that the use of GH as a doping agent in sports is widespread, little is known about its short-term effects. OBJECTIVE: The objective was to study the effects of GH on exercise capacity. DESIGN: A double-blind, placebo-controlled study was used, with a treatment period of 28 d. SETTING: Subjects from general community studied ambulatory at a university hospital. PARTICIPANTS: Thirty healthy active young normal volunteers (15 women and 15 men) were recruited by local announcement, and all completed the study. INTERVENTION: All subjects were randomized to receive a low GH dose (0.033 mg/kg.d or 0.1 IU/kg.d), a high GH dose (0.067 mg/kg.d or 0.2 IU/kg.d), or placebo. MAIN OUTCOME MEASURES: Power output and oxygen uptake on bicycle exercise were the main outcome measures. RESULTS: We found no effect of the low or high dosages of GH on maximum oxygen uptake during exercise (mean +/- se for placebo, 45.2 +/- 1.6 to 45.2 +/- 2.1 ml/kg.min; GH low dose, 42.8 +/- 1.6 to 42.8 +/- 1.6 ml/kg.min; GH high dose, 44.8 +/- 3.4 to 44.8 +/- 2.2 ml/kg.min; not significant by two-way ANOVA). Neither was there any effect on maximum achieved power output during exercise or on blood pressure, heart rate, or the electrocardiographic ST level at rest or during exercise. GH significantly increased total body weight (P = 0.028), an effect predominantly ascribed to fluid retention (increased extracellular water volume), whereas muscle mass (as indicated by intracellular water volume) did not change. However, changes in the latter correlated to changes in physical performance, possibly due to different training efforts. CONCLUSION: Administration of supraphysiological recombinant human GH during a period of 4 wk does not improve power output or oxygen uptake.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2004-1209

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Berggren, A., Ehrnborg, C., Rosén, T., Ellegård, L., Bengtsson, B.-A., & Caidahl, K.
Affiliations
  • Departments of Clinical Physiology (A.B., K.C.), SE-41345 Göteborg, Sweden
  • Endocrinology (C.E., T.R., B.-Å.B.), SE-41345 Göteborg, Sweden
  • Clinical Nutrition (L.E.), Sahlgrenska University Hospital, SE-41345 Göteborg, Sweden
  • Karolinska Institutet (SE)
Corresponding author
Caidahl, Kenneth
ORCID
Caidahl, Kenneth
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
2005-06-01
Volume
90
Issue
6
Pages
3268-3273
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
DOI
10.1210/jc.2004-1209
OpenAlex
W1983342131
Cited by
73
References
42
Citations by year
2024: 1 · 2022: 1 · 2021: 1 · 2019: 3 · 2018: 2 · 2017: 2 · 2016: 1 · 2015: 2 · 2014: 1 · 2013: 2 · 2012: 5
FWCI
6.42
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • European Commission
  • Hjärt-Lungfonden
  • International Olympic Committee
  • Medical Research Council
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Social Sciences › Sociology and Political Science › Doping in Sports
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Physical Performance
Keywords
recombinant human growth hormone, endurance exercise capacity, VO2max, output power, doping in sport, fluid retention, weight gain, muscle mass, insulin-like growth factor I
MeSH terms
Blood Pressure, Body Water, Carbon Dioxide, Double-Blind Method, Female, Humans, Insulin-Like Growth Factor I, Male, Oxygen, Oxygen Consumption, Partial Pressure, Physical Endurance, Placebos, Reference Values, Exercise, Human Growth Hormone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review